ObesityACTION-APACNCT05250427
Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific
An observational study of Obesity, run by Novo Nordisk A/S at 9 sites in 9 countries.
Trial summary
ACTION APAC is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity
- What is being tested?
- No treatment given
- How many people
- 12,404 participants
- Where
- 9 sitesin 9 countries
- Study dates
- 26 Apr 2022to 23 May 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The respondent population will include people living with obesity (PLwO) and health care professionals (HCPs) involved in obesity treatment and management.
Who may be able to join
- People Living with Obesity
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, aged above or equal to 18 years at the time of signing informed consent
- Lives in one of the target countries
- Current BMI of at least 25 kg/m^2 for all countries (except Singapore which has current BMI 27 kg/m^2) based on self-reported height and weight
- Health Care Professionals
Show all 17Show fewer
- Informed consent before any study related activities (study-related activities are any procedure related to recording/collection of data according to protocol)
- Male or female, aged greater than or equal to 18 years at the time of signing informed consent.
- Physician
- Primary Care Providers (PCPs) whose specialty is Family practice, General practice, Internal Medicine
- Non-PCP Specialties whose specialty is Endocrinologist, Cardiologist, Gastroenterologist, Obstetrics/Gynaecologist, Bariatrics/Obesity Medicine, Nutrition Specialist (physician) Orthopaedist, Aesthetics Medicine
- Specialty is not surgeon (including bariatric or plastic surgeon)
- Practices in the target countries
- In clinical practice for at least 2 years
- Spends at least 50% time in direct patient care
- Has seen at least 100 patients in past month
- Has seen at least 10 patients in past month who have obesity defined as: a patient with a BMI greater than or equal to 25 kg/m^2 for all countries (except Singapore which has current greater than or equal to BMI 27 kg/m^2) with or without comorbidities.
Who cannot join
- People Living with obesity
- Previous participation in this study. Participation is defined as having given online consent in this study
- Currently pregnant
- Participates in intense fitness or body building programs
- Has had significant, unintentional weight loss (due to major injury, illness, etc) in the past 6 months
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Show all 9Show fewer
- Health Care Providers
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Unwillingness, inability, or language barriers precluding adequate understanding or cooperation
Trial locations and contacts
9 sites in 9 countries.
9 sites in 9 countries
About this study
ACTION APAC is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor through existing databases/panels in APAC region.
The goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.
- Conditions
- Obesity
- Being tested
- No treatment given
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No treatment givenOther
No treatment given
| Study group | Role | What they receive |
|---|---|---|
| People / Person Living with Obesity (PLwO) | From online, general population consumer panels Receives: Other: No treatment given | |
| Health Care Professionals (HCPs) | HCPs treating people who have obesity Receives: Other: No treatment given |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight loss motivators for improving health of PLwO
Multi-select from defined list
Measured: At the time of survey response (Day 1)
Weight loss barriers for improving health of PLwO
Multi-select from defined list
Measured: At the time of survey response (Day 1)
Weight loss management for improving health of PLwO
Multi-select from defined list
Measured: At the time of survey response (Day 1)
Weight loss responsibility for improving health of PLwO
Multi-select from defined list
Measured: At the time of survey response (Day 1)
Proportion of PLwO who made serious weight loss effort
Number of weight loss efforts; percentage of patients
Measured: At the time of survey response (Day 1)
Response to weight loss discussions
Single select from defined list
Measured: At the time of survey response (Day 1)
Attitudes towards obesity and weight management and Interactions of PLwOs with HCPs
5-point Likert scales
Measured: At the time of survey response (Day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2022
- Study start26 Apr 2022
- Primary completion23 May 2022
- Study completion23 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 12,404 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05250427
- Sponsor's protocol ID
- DAS-006
- Other IDs
- U1111-1266-5484
- Acronym
- ACTION-APAC
- Status last verified
- Jun 2022
- First submitted
- 11 Feb 2022
- Last updated
- 14 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Publications
Unnikrishnan AG, Chowdhury S, Garcia MM, Jain RK, John M, Lakdawala M, Pai R, Suresh SH, Rahman SK. Perceptions, attitudes and barriers to effective obesity care among people with obesity and health care professionals in India. Diabetes Obes Metab. 2024 Oct;26(10):4791-4794. doi: 10.1111/dom.15824. Epub 2024 Aug 5. No abstract available.
PubMed 39101238
Study at a glance
From the registry record, last updated by the sponsor on 14 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific
- ClinicalTrials.gov ID
- NCT05250427
- Acronym / sponsor ID
- ACTION-APAC / DAS-006
- Conditions
- Obesity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 12,404 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 26 Apr 2022 (actual)
- Primary completion
- 23 May 2022 (actual)
- Study completion
- 23 May 2022 (actual)
- First posted
- 22 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ACTION APAC is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor through existing databases/panels in APAC region.
The goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| People / Person Living with Obesity (PLwO) | – | Other: No treatment givenFrom online, general population consumer panels |
| Health Care Professionals (HCPs) | – | Other: No treatment givenHCPs treating people who have obesity |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The respondent population will include people living with obesity (PLwO) and health care professionals (HCPs) involved in obesity treatment and management.
Key inclusion criteria (17 listed)
- People Living with Obesity
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, aged above or equal to 18 years at the time of signing informed consent
- Lives in one of the target countries
- Current BMI of at least 25 kg/m^2 for all countries (except Singapore which has current BMI 27 kg/m^2) based on self-reported height and weight
Key exclusion criteria (9 listed)
- People Living with obesity
- Previous participation in this study. Participation is defined as having given online consent in this study
- Currently pregnant
- Participates in intense fitness or body building programs
- Has had significant, unintentional weight loss (due to major injury, illness, etc) in the past 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No treatment givenNo treatment given | Other | Health Care Professionals (HCPs), People / Person Living with Obesity (PLwO) |
Primary outcome
Weight loss motivators for improving health of PLwO
Time frame: At the time of survey response (Day 1)
Multi-select from defined list
Weight loss barriers for improving health of PLwO
Time frame: At the time of survey response (Day 1)
Multi-select from defined list
Weight loss management for improving health of PLwO
Time frame: At the time of survey response (Day 1)
Multi-select from defined list
Weight loss responsibility for improving health of PLwO
Time frame: At the time of survey response (Day 1)
Multi-select from defined list
Proportion of PLwO who made serious weight loss effort
Time frame: At the time of survey response (Day 1)
Number of weight loss efforts; percentage of patients
Response to weight loss discussions
Time frame: At the time of survey response (Day 1)
Single select from defined list
Attitudes towards obesity and weight management and Interactions of PLwOs with HCPs
Time frame: At the time of survey response (Day 1)
5-point Likert scales
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jun 2022.
- Derived from this study: PubMed 39101238Unnikrishnan AG, Chowdhury S, Garcia MM, Jain RK, John M, Lakdawala M, Pai R, Suresh SH, Rahman SK. Perceptions, attitudes and barriers to effective obesity care among people with obesity and health care professionals in India. Diabetes Obes Metab. 2024 Oct;26(10):4791-4794. doi: 10.1111/dom.15824. Epub 2024 Aug 5. No abstract available.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Transparency (dept. 2834) study director
Novo Nordisk A/S
9 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity, run by Novo Nordisk A/S at 9 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Bangladesh, India, Indonesia, Malaysia, Pakistan and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight loss motivators for improving health of PLwO (time frame: At the time of survey response (Day 1)). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05250427, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jun 2022; AzTrials last refreshed its copy on 8 Nov 2026.